Novo Nordisk now sells three FDA-approved products built on the same active ingredient, semaglutide: injectable Wegovy, the diabetes pill Rybelsus, and, as of December 2025, oral Wegovy. Because they share a molecule but differ in dose, formulation, and approved use, it’s easy to conflate them. Here’s how the three actually compare.
Same Molecule, Three Products
All three products deliver semaglutide, a GLP-1 receptor agonist. What differs is the delivery method, the dose range, and, critically, the FDA-approved indication for each one, which determines what a doctor can prescribe it for and how insurance evaluates coverage.
Injectable Wegovy
Injectable Wegovy was the first of the three, approved in 2021 for chronic weight management in adults (and later some adolescents) with obesity or overweight plus a weight-related condition. It’s a once-weekly subcutaneous injection, with doses escalating up to 2.4 mg, and its efficacy record includes the STEP trial program discussed elsewhere on this site.
Rybelsus
Rybelsus, approved in 2019, is an oral semaglutide tablet, but it’s approved only for type 2 diabetes, not weight management, and its dosing tops out at 14 mg daily — well below the semaglutide exposure achieved by the higher-dose oral Wegovy tablet. Rybelsus is sometimes used off-label for weight loss, but it isn’t studied or approved for that use at its approved dose range.
Oral Wegovy
Oral Wegovy, approved in December 2025, is a separate, higher-dose oral tablet, scaling up to 25 mg, specifically approved for chronic weight management — the same indication as injectable Wegovy. It’s built on trial data from OASIS-4, where adherent patients lost an average of 16.6% of body weight versus 2.7% on placebo.
Efficacy Side by Side
Cross-trial comparisons come with caveats, since STEP 1 (injectable) and OASIS-4 (oral) enrolled different patient populations at different times. With that caveat, Novo Nordisk has described the two sets of results as broadly consistent, and an indirect comparison presented at ObesityWeek 2025 suggested comparable efficacy between the formulations. Rybelsus, at its diabetes-approved dose, isn’t a fair efficacy comparison for weight loss, since it wasn’t studied at the higher doses used in the weight-management trials.
Which One a Doctor Might Consider
The relevant factors are the approved indication (diabetes versus weight management), a patient’s comfort with an injection versus a pill with a specific empty-stomach dosing routine, cost and insurance coverage — which varies by product and by payer — and any individual medical history that could favor one option. These are exactly the kind of tradeoffs a prescriber weighs for a specific patient, not something this article can resolve in the abstract.
Talk to a Doctor
Because these three products differ in approved use, dose, and administration, switching between them, or choosing among them, should be a conversation with a prescriber familiar with your medical history, not a decision based on a general comparison like this one.